Cinctive Capital Management LP Purchases Shares of 32,494 Vaxcyte, Inc. (NASDAQ:PCVX)

Cinctive Capital Management LP acquired a new position in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 32,494 shares of the company's stock, valued at approximately $3,713,000.

Several other institutional investors have also recently modified their holdings of PCVX. China Universal Asset Management Co. Ltd. raised its holdings in Vaxcyte by 68.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 21,466 shares of the company's stock valued at $2,453,000 after acquiring an additional 8,685 shares during the last quarter. Harbor Capital Advisors Inc. lifted its position in Vaxcyte by 392.4% during the second quarter. Harbor Capital Advisors Inc. now owns 40,342 shares of the company's stock worth $3,046,000 after buying an additional 32,149 shares during the period. Natixis Advisors LLC lifted its position in Vaxcyte by 61.1% during the third quarter. Natixis Advisors LLC now owns 22,697 shares of the company's stock worth $2,594,000 after buying an additional 8,606 shares during the period. Tri Locum Partners LP purchased a new stake in Vaxcyte in the 2nd quarter valued at about $8,559,000. Finally, Hsbc Holdings PLC acquired a new position in Vaxcyte during the second quarter worth approximately $1,053,000. 96.78% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Vaxcyte

In other news, CFO Andrew Guggenhime sold 8,000 shares of the stock in a transaction on Wednesday, September 18th. The stock was sold at an average price of $115.94, for a total value of $927,520.00. Following the completion of the transaction, the chief financial officer now owns 90,383 shares of the company's stock, valued at approximately $10,479,005.02. This represents a 8.13 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Grant Pickering sold 2,366 shares of the company's stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $103.89, for a total transaction of $245,803.74. Following the completion of the sale, the chief executive officer now directly owns 137,398 shares of the company's stock, valued at $14,274,278.22. The trade was a 1.69 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 87,464 shares of company stock worth $9,797,926 over the last quarter. 3.10% of the stock is owned by corporate insiders.

Vaxcyte Stock Down 0.5 %

Shares of PCVX traded down $0.49 during trading on Tuesday, reaching $91.11. The company's stock had a trading volume of 324,116 shares, compared to its average volume of 904,309. Vaxcyte, Inc. has a twelve month low of $52.74 and a twelve month high of $121.06. The company has a market cap of $11.36 billion, a price-to-earnings ratio of -19.91 and a beta of 0.94. The company has a fifty day moving average of $105.60 and a two-hundred day moving average of $90.49.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last released its earnings results on Tuesday, November 5th. The company reported ($0.83) earnings per share for the quarter, topping the consensus estimate of ($1.10) by $0.27. During the same quarter in the prior year, the company posted ($0.91) earnings per share. As a group, equities analysts forecast that Vaxcyte, Inc. will post -4.14 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on PCVX. BTIG Research boosted their price objective on shares of Vaxcyte from $98.00 to $160.00 and gave the company a "buy" rating in a research note on Tuesday, September 3rd. Leerink Partners raised their price objective on Vaxcyte from $106.00 to $153.00 and gave the stock an "outperform" rating in a report on Tuesday, September 3rd. Bank of America boosted their target price on Vaxcyte from $101.00 to $140.00 and gave the stock a "buy" rating in a report on Wednesday, September 4th. Needham & Company LLC restated a "buy" rating and issued a $140.00 price target on shares of Vaxcyte in a report on Wednesday, November 6th. Finally, Cantor Fitzgerald reiterated an "overweight" rating on shares of Vaxcyte in a research note on Wednesday, November 6th. Seven analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average price target of $147.50.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.